Introduction
============

Although vitamin D is recognized mainly for its effects on bone metabolism, it is also known that it regulates multiple aspects of cellular differentiation and replication in many target tissues, including endocrine pancreas.[@b1-tacg-9-131],[@b2-tacg-9-131] Some studies have suggested that vitamin D plays an important role in the mechanism of insulin release and in the maintenance of glucose tolerance and have also shown the association between vitamin D deficiency and Type 2 diabetes (T2DM).[@b3-tacg-9-131],[@b4-tacg-9-131]

Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in patients with diabetes and the largest contributor to the cost of diabetes.[@b5-tacg-9-131] Various studies have also suggested the association between reduced 25-hydroxyvitamin D (25OHD) concentrations and an increased risk of atherosclerosis, endothelial dysfunction, and coronary artery disease (CAD).[@b6-tacg-9-131]--[@b9-tacg-9-131]

Recent developments have led public health authorities to take an increasing interest in vitamin D research, since vitamin D deficiency is highly prevalent in the general population,[@b10-tacg-9-131] even in those living in areas with abundant sunlight.[@b11-tacg-9-131],[@b12-tacg-9-131]

It is well known that metabolic actions related to vitamin D, on target cells, are mediated by the binding of 1,25-dihydroxyvitamin D to its specific cytosolic/nuclear receptor, which has been identified in many tissues.[@b13-tacg-9-131] The vitamin D receptor (VDR) is a member of the steroid/thyroid hormone receptor family and functions as a transcriptional activator of many genes.[@b14-tacg-9-131] The VDR gene is located on chromosome 12q13.11 in humans and consists of eleven exons.[@b15-tacg-9-131] Several polymorphisms of the VDR gene have been identified, but four single-nucleotide polymorphisms (SNPs) of this gene are the ones that have been most studied, namely, *BsmI* (rs1544410), *ApaI* (rs7975232), *TaqI* (T\>C; rs731236), and *FokI* (C\>T; rs2228570, formerly known as rs10735810).

The *FokI* polymorphism occurs in the start codon of VDR and its polymorphic form (f) leads to the translation of a longer VDR protein variant (427 amino acid), and some in vitro studies suggest that it functions less effectively than the shorter VDR protein (424 amino acid) encoded by the F allele.[@b15-tacg-9-131]--[@b17-tacg-9-131] The functional activity of this SNP is yet to be fully understood, since other in vitro experiments have failed to show this difference.[@b18-tacg-9-131] *TaqI* polymorphism results from a mutation in a transcriber region located in exon 9 of the VDR gene. However, there are no studies demonstrating its functionality.[@b15-tacg-9-131]

Several studies in recent years have attempted to elucidate the possible relationship between polymorphisms of the VDR gene and diabetes and CVD, but the results are still controversial and substantial differences have been observed between SNPs and the ethnic groups analyzed.[@b19-tacg-9-131]--[@b26-tacg-9-131] This further emphasizes the need to conduct studies to analyze VDR polymorphisms in different ethnic populations.

The aims of this study were, therefore, to access the genotypic distribution of *FokI* and *TaqI* polymorphisms of VDR in a population of postmenopausal women with T2DM and in a control group, and to evaluate whether these two SNPs of VDR (*FokI* and *TaqI*) are associated with micro- and macrovascular complications.

Methods
=======

Study design
------------

This cross-sectional study was carried out between September 2013 and August 2014 in the city of Recife (Brazil) and comprised 100 female patients with physiological menopause and diagnosis of T2DM, according to the American Diabetes Association criteria.[@b5-tacg-9-131] A total of 100 postmenopausal women without diabetes were enrolled as the control group. The subjects of the study were recruited from the community. The study was approved by the Ethics in Research Committee of Agamenon Magalhães Hospital (CEP-HAM, Recife, Brazil). All patients gave their written informed consent to take part in this study.

The exclusion criteria were as follows: patients with Type 1 diabetes; end-stage renal disease; use of glucocorticoids; use of vitamin D replacement therapy; use of hormone replacement therapy; primary hyperparathyroidism; Paget's disease of bone; malabsorption syndrome; and/or active neoplasia.

The patients were interviewed by a physician, answered a standard questionnaire, and underwent a complete physical examination, including measurement of height, weight, waist circumference, and blood pressure. Skin phototypes were classified in six types, according to Fitzpatrick's classification (Type 1 as the lightest and Type 6 as the darkest).[@b27-tacg-9-131] Blood samples were obtained from all participants, after overnight fasting. Low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride levels, fasting blood glucose, and glycated hemoglobin (HbA1c) were evaluated. Biochemical tests were processed in a dry chemistry autoanalyzer (Vitro System, Johnson & Johnson, New Brunswick, NJ, USA) and HbA1c concentrations were determined by immunoturbidimetric assay (Cobas 501, Roche Diagnostic, Rotkreuz, Switzerland).

Serum 25OHD levels were measured by electrochemi-luminescent competitive immunoassay (Diasorin-Liaison, Saluggia, Italy), with the interassay and intra-assay coefficients of variation of 8%--15% and 8%--13%, respectively, with a minimum limit of detection of 2 ng/mL.[@b28-tacg-9-131]

DNA extraction and genotyping
-----------------------------

The DNA was extracted from whole blood samples (ethylenediaminetetraacetic acid) using the QIAamp Mini Spin Columns kit (QIAGEN, Venlo, the Netherlands) in accordance with the manufacturer's instructions. For detection of polymorphic variable, the real-time polymerase chain reaction method in the TAQMAN® (Thermo Fisher Scientific, Waltham, MA, USA) system was used.

We genotyped the following SNP of the VDR gene: *FokI* (rs10735810/ID: C\_\_12060045_20) and *TaqI* (rs731236/ID:C\_\_\_2404008_10) according to the manufacturer's instructions (<http://www.thermofisher.com/order/genome-database>). *FokI* polymorphism results in different translation initiation sites due to the replacement of cytosine (C) by thymine (T) and *TaqI* polymorphism is constituted by the silent replacement of thymine (T) by cytosine (C).

Statistical evaluation
----------------------

Data for categorical variables are presented as numbers (percentages), and data for continuous variables are presented as mean values (standard deviations). The differences in genotype and allele frequencies were analyzed by Pearson's chi-square test and Fisher's exact test. Differences were considered statistically significant for *P*-values of less than 0.05. Odds ratio (OR) with a 95% confidence interval (CI) was determined to estimate the association between variables. The GraphPad Prism program (version 6.0) for Windows (GraphPad Software, San Diego, CA, USA) was used for the analysis. To determine the Hardy--Weinberg equilibrium in the population, the ARLEQUIN program was used (version 3.11, Bern, Swiss).

Results
=======

The clinical characteristics of the patients and control group are summarized in [Table 1](#t1-tacg-9-131){ref-type="table"}. Age distribution between T2DM patients (65.7±7.18 years) and controls (65.1±9.18 years) was not significantly different (*P*=0.1608). The frequency of hypertension and body mass index \>25 kg/m^2^ were higher in the T2DM patients than in the controls (*P*=0.0001 and *P*=0.0355, respectively). Mean waist circumference, serum triglyceride levels, and HbA1c were elevated in patients compared with controls. There were no significant differences in skin phototype between patients and controls. Serum 25OHD levels below 30 ng/mL were found to be significantly more prevalent in T2DM patients than in the control group (74% and 48%, respectively; *P*=0.0001). Using cutoffs for serum 25OHD levels below 20 ng/mL, the prevalence of vitamin D deficiency was 12% in patients with diabetes and 7% in the control group (*P*=0.3350).

There were no significant differences in genotype and allele frequency distribution between T2DM patients and controls in either the *TaqI* or *FokI* analysis ([Tables 2](#t2-tacg-9-131){ref-type="table"} and [3](#t3-tacg-9-131){ref-type="table"}). The prevalence of *TaqI* genotypes was 45% TT, 46% Tt, 9% tt in T2DM patients, and 49% TT, 39% Tt, and 12% tt in the control group ([Table 2](#t2-tacg-9-131){ref-type="table"}). The frequency of the T allele in T2DM patients was 68% and that of the t allele 32%, while in the control group, it was 68.5% and 31.5%, respectively (*P*=1.0000; [Table 2](#t2-tacg-9-131){ref-type="table"}). The prevalence of *FokI* was 46% FF, 42% Ff, and 12% ff in T2DM patients and 38% FF, 47% Ff, and 15% ff in the control group. The frequency of the F allele in T2DM patients was 67% and that of the f allele 33%, while in the control group, it was 61.5% and 38.5%, respectively (*P*=0.1256). The study subjects were in Hardy--Weinberg equilibrium for both *TaqI* and *FokI.*

In addition, we also compared the VDR (*TaqI* and *FokI*) genotypes and allele frequencies with the presence of macro- and microvascular complications of diabetes. There were no significant differences in relation to stroke, retinopathy, nephropathy, or neuropathy. No statistically significant differences were found in the TaqI genotype or allele frequency in the groups of patients with diabetes and without a history of CAD ([Table 4](#t4-tacg-9-131){ref-type="table"}), but in the *FokI* analysis ([Table 5](#t5-tacg-9-131){ref-type="table"}), compared with genotype FF, genotype Ff was likely to be a protective factor for CAD (FF vs Ff, *P*=0.0391, OR 0.29, 95% CI 0.09--1.01). We also found a significant association between *FokI* polymorphism and CAD in the recessive model (FF vs Ff + ff, *P*=0.0462, OR 0.35, 95% CI 0.12--1.02).

Discussion
==========

In our study, no significant differences were found in genotype and allele frequency distribution of VDR (*TaqI* and *FokI*) genes between postmenopausal Brazilian women with T2DM and those of the control group. However, in T2DM patients with a history of CAD, we observed a lower frequency of the Ff genotype (*P*=0.0361) and the combination of genotypes Ff + ff (*P*=0.0462).

The prevalence of VDR *TaqI* and *FokI* polymorphism genotypes was similar to data reported previously in another study that also analyzed Brazilian postmenopausal women.[@b29-tacg-9-131]

Reports on the association between VDR gene polymorphisms and T2DM have been inconsistent. Our analysis did not find any evidence of an association between *TaqI* and *FokI* polymorphism and T2DM among Brazilian postmenopausal women. Two meta-analyses showed data similar to ours regarding the lack of evidence of any association of the *TaqI* polymorphism with T2DM.[@b30-tacg-9-131],[@b31-tacg-9-131] However, with regard to the *FokI* polymorphism, these meta-analyses found some statistical evidence that the f allele may be a susceptibility allele for T2DM in an Asian population.[@b30-tacg-9-131],[@b31-tacg-9-131] It is important to emphasize that this result may vary according to the study population because of substantial differences in VDR polymorphisms between races, which have already been demonstrated.[@b15-tacg-9-131] In fact, a study in Polish Caucasians found a result similar to ours, with no evidence for an association of *FokI* polymorphism with T2DM.[@b22-tacg-9-131]

We likewise found no association between *TaqI* polymorphism and CAD among postmenopausal Brazilian women with T2DM. A prospective study found a significant association between the t allele of *TaqI* VDR and baseline cases of CAD in a French population.[@b24-tacg-9-131] On the other hand, in a study of the Egyptian population, the *TaqI* showed no significant association with CAD.[@b32-tacg-9-131] As it has been suggested that the *TaqI* polymorphism is a silent mutation, it results in no amino acid sequence change.[@b15-tacg-9-131] This evidence may partly explain the result of this study.

The analysis of *FokI* SNPs of VDR, in our study, showed that the Ff genotype is probably a protective factor for CAD in postmenopausal women with T2DM; moreover, when we compared a recessive model for analysis (Ff + ff), there was a significant association with CAD.

Accumulating evidence suggests that low serum levels of vitamin D are associated with an increased risk of atherosclerosis, endothelial dysfunction, and CVD.[@b6-tacg-9-131],[@b7-tacg-9-131],[@b33-tacg-9-131],[@b34-tacg-9-131] The epigenetic effects of vitamin D include modulation of smooth muscle cell proliferation, vascular calcification, inflammation, and thrombosis.[@b35-tacg-9-131]--[@b37-tacg-9-131] In addition, vitamin D is a negative regulator of renin--angiotensin.[@b38-tacg-9-131]--[@b40-tacg-9-131] VDR polymorphism is thus a potential candidate for coronary atherosclerosis.

Ortlepp et al[@b20-tacg-9-131] reported no association between *BsmI* polymorphism of VDR and coronary angiographic phenotypes in a large study population. A cohort from a multinational prospective study found that the haplotype comprising the minor allele of *BsmI*, the major allele of *ApaI*, and the minor allele of *TaqI* of VDR was associated with an increased risk of CAD in T2DM patients.[@b24-tacg-9-131] Our study did not evaluate the *ApaI* and *BsmI* polymorphisms; it did, however, analyze the *FokI* SNP, which is considered to be an independent marker of the VDR gene because it is not in linkage disequilibrium with other VDR SNPs, and there is speculation on its possible relationship with the functionality of the VDR protein.[@b15-tacg-9-131]

With regard to the association of genotype and allele frequencies of the *FokI* polymorphism with CAD, a Chinese study observed no significant evidence.[@b41-tacg-9-131] Another study in a Caucasian population found no significant differences in anthropometric and biochemical features of CVD between genotypes of *FokI* in female and male groups,[@b42-tacg-9-131] but it is difficult to compare those findings with ours because of differences in the study population. Both studies analyzed men and women in general, while our population is specific to postmenopausal women with T2DM.

Our findings cannot be related to the VDR functionality of *FokI* SNP, since the studies on functional differences in the VDR protein encoded by the polymorphic form are conflicting, suggesting the need for further studies on this topic.

Vaidya et al[@b43-tacg-9-131] observed that both higher serum 25OHD levels and the f allele at *FokI* were independently associated with lower plasma renin activity in a large population of hypertensives.[@b43-tacg-9-131] As plasma renin activity is associated with CVD, this finding is consistent with our finding of an association between the recessive model of *FokI* (Ff + ff) and CAD.

Our data therefore suggest that the association observed between the recessive model of *FokI* polymorphism and CAD in postmenopausal women with T2DM as a protective factor may be mediated by modulation of the renin--angiotensin system. However, additional studies with a larger sample size across various ethnic groups are needed to fully determine such an association and clarify the mechanism involved.

Some potential limitations should be considered in this study, such as the small size of the study population, the cross-sectional design of the study, and the fact that patients did not undergo diagnostic angiography, and so there is a possibility that patients with asymptomatic CAD were overlooked.

Conclusion
==========

Our study suggests that the *FokI* polymorphism in the VDR gene is a protective factor for CAD in postmenopausal women with T2DM in the recessive model. Our data evidenced no association between the polymorphisms analyzed (*FokI* and *TaqI*) and T2DM and other chronic complications of diabetes.
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###### 

Characteristics of study participants

  Characteristics                          Cases          Control        *P*-value
  ---------------------------------------- -------------- -------------- --------------------------------------------------------------------------------------------------
  Age                                                                    
  Mean (±SD)                               65.7 (±7.18)   65.1 (±9.18)   *P*[a](#tfn2-tacg-9-131){ref-type="table-fn"}=0.16
  Hypertension (n)                                                       
   Yes                                     86             60             
   No                                      14             40             *P*[b](#tfn3-tacg-9-131){ref-type="table-fn"}=0.0001[\*](#tfn1-tacg-9-131){ref-type="table-fn"}
  BMI (kg/m^2^) (n)                                                      
   Normal (\<25)                           19             33             
   Overweight/obese (\>25)                 81             67             *P*[b](#tfn3-tacg-9-131){ref-type="table-fn"}=0.0355[\*](#tfn1-tacg-9-131){ref-type="table-fn"}
  WC (cm)                                                                
   Mean (±SD)                              99 (±12)       89 (±14)       *P*[a](#tfn2-tacg-9-131){ref-type="table-fn"}\<0.0001[\*](#tfn1-tacg-9-131){ref-type="table-fn"}
  HbA1c (%)                                                              
   Mean (±SD)                              7.8 (±1.7)     5.5 (±0.3)     *P*[a](#tfn2-tacg-9-131){ref-type="table-fn"}\<0.0001[\*](#tfn1-tacg-9-131){ref-type="table-fn"}
  Triglycerides (mg/dL)                                                  
   Mean (±SD)                              160 (±68)      135 (±62)      *P*[a](#tfn2-tacg-9-131){ref-type="table-fn"}=0.0200[\*](#tfn1-tacg-9-131){ref-type="table-fn"}
  Skin phototype(n)                                                      
   I + II                                  6              3              
   III + IV                                70             58             *P*[b](#tfn3-tacg-9-131){ref-type="table-fn"}=0.73
   V + VI                                  24             39             *P*[b](#tfn3-tacg-9-131){ref-type="table-fn"}=0.15
  25OHD (ng/mL) (n)                                                      
   Deficiency/insufficiency (\<30 ng/mL)   74             48             
   Normal (\>30 ng/mL)                     26             52             *P*[b](#tfn3-tacg-9-131){ref-type="table-fn"}=0.0001[\*](#tfn1-tacg-9-131){ref-type="table-fn"}

**Notes:**

Statistically significant difference (*P*\<0.05);

Student's *t*-test;

Fisher's exact test.

**Abbreviations:** SD, standard deviation; BMI, body mass index; WC, waist circumference; HbA1c, glycated hemoglobin; 25OHD, 25-hydroxyvitamin D.

###### 

Distribution of VDR (*TaqI*) polymorphism genotypes and allele frequencies between T2DM patients and control groups

  VDR                 T2DM patients n=100   Control n=100   *P*-value[a](#tfn5-tacg-9-131){ref-type="table-fn"}   OR     95% CI
  ------------------- --------------------- --------------- ----------------------------------------------------- ------ ------------
  Genotype                                                                                                               
  AA (TT)             45 (45%)              49 (49%)        --                                                           
  AG (Tt)             46 (46%)              39 (39%)        0.45                                                  1.28   0.68--2.41
  GG (tt)             9 (9%)                12 (12%)        0.81                                                  0.82   0.28--2.33
  AG + GG (Tt + tt)   55 (55%)              52 (52%)        0.67                                                  1.17   0.65--2.13
  Alleles                                                                                                                
  A (T)               136 (68%)             137 (68.5%)     --                                                           
  G (t)               64 (32%)              63 (31.5%)      1.00                                                  1.02   0.66--1.59

**Notes:**

Chi-square test. "--" indicates no data.

**Abbreviations:** VDR, vitamin D receptor; T2DM, Type 2 diabetes; OR, odds ratio; CI, confidence interval.

###### 

Distribution of VDR (*FokI*) polymorphism genotypes and allele frequencies between T2DM patients and control groups

  VDR                 T2DM patients n=100   Control n=100   *P*-value[a](#tfn7-tacg-9-131){ref-type="table-fn"}   OR     95% CI
  ------------------- --------------------- --------------- ----------------------------------------------------- ------ ------------
  Genotype                                                                                                               
  GG (FF)             46 (46%)              38 (38%)        --                                                           
  AG (Ff)             42 (42%)              47 (47%)        0.13                                                  1.4    0.77--2.56
  AA (ff)             12 (12%)              15 (15%)        0.17                                                  1.5    0.63--3.62
  AG + GG (Ff + ff)   54 (54%)              62 (62%)        0.13                                                  1.39   0.79--2.44
  Alleles                                                                                                                
  G (F)               134 (67%)             123 (61.5%)     --                                                           
  A (f)               66 (33%)              77 (38.5%)      0.13                                                  1.2    0.84--1.91

**Notes:**

Chi-square test. "--" indicates no data.

**Abbreviations:** VDR, vitamin D receptor; T2DM, Type 2 diabetes; OR, odds ratio; CI, confidence interval.

###### 

Distribution of VDR (*TaqI*) polymorphism genotypes and allele frequencies in T2DM patients according to the presence of CAD

  CAD                                        
  ------------------- ---------- ----------- ------
  Genotype                                   
  AA (TT)             8 (44%)    37 (45%)    
  AG (Tt)             7 (39%)    39 (48%)    0.78
  GG (tt)             3 (17%)    6 (7%)      0.37
  AG + GG (Tt + tt)   10 (56%)   45 (55%)    1.00
  Alleles *n (%)*                            
  A (T)               23 (64%)   113 (69%)   
  G (t)               13 (36%)   51 (31%)    0.56

**Note:**

Chi-square test.

**Abbreviations:** VDR, vitamin D receptor; T2DM, Type 2 diabetes; CAD, coronary artery disease.

###### 

Distribution of VDR (*FokI*) polymorphism genotypes and allele frequencies in T2DM patients according to the presence of CAD

  CAD                                                                                                  
  ----------------- ---------- ----------- ---------------------------------------------------- ------ ------------
  Genotype                                                                                             
  GG (FF)           12 (67%)   34 (42%)    --                                                          
  AG (Ff)           4 (22%)    38 (46%)    0.0361[\*](#tfn11-tacg-9-131){ref-type="table-fn"}   0.29   0.09--1.01
  AA (ff)           2 (11%)    10 (12%)    0.39                                                 0.57   0.11--2.96
  AG + AA           6 (33%)    48 (58%)    0.0462[\*](#tfn11-tacg-9-131){ref-type="table-fn"}   0.35   0.12--1.02
  (Ff + ff)                                                                                            
  Alleles *n (%)*                                                                                      
  G (F)             28 (78%)   106 (65%)   --                                                          
  A (f)             8 (22%)    58 (35%)    0.09                                                 0.52   0.22--1.22

**Notes:**

Statistically significant difference (*P*\<0.05);

Chi-square test. "--" indicates no data.

**Abbreviations:** VDR, vitamin D receptor; T2DM, Type 2 diabetes; OR, odds ratio; CI, confidence interval; CAD, coronary artery disease.
